Lung Cancer Clinical Trials

• Participant has provided informed consent before initiation of any study-specific activities/procedures.

• Age ≥ 18 years or ≥ legal age within the country if it is older than 18 years.

• Histologically or cytologically documented ES-SCLC (American Joint Committee on Cancer, 2017, Stage IV SCLC \[T any, N any, M1 a/b/c\]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan.

• Measurable disease as defined per RECIST 1.1.

• Suitable to receive carboplatin, etoposide and durvalumab regimen as first-line treatment per investigator clinical assessment.

• Minimum life expectancy ≥ 12 weeks.